Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer. - Wikidata - awgldk - TriplyDB

Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.

Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.

http://www.wikidata.org/entity/Q42506718

about

A perspective on anti-EGFR therapies targeting triple-negative breast cancer Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers.Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.Spectrum of EGFR gene copy number changes and KRAS gene mutation status in Korean triple negative breast cancer patients.Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract.Anaplastic lymphoma kinase gene copy number gain in inflammatory breast cancer (IBC): prevalence, clinicopathologic features and prognostic implication.Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.ALK alteration is a frequent event in aggressive breast cancers.Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications.Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma.ALK gene amplification is associated with poor prognosis in colorectal carcinoma Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers.Inside out: targeting NHE1 as an intracellular and extracellular regulator of cancer progression.Therapeutic targets in triple negative breast cancer.PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.Emerging targeted agents in metastatic breast cancer.PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?Shotgun proteomics of archival triple-negative breast cancer samples.Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer Analysis of ALK gene in 133 patients with breast cancer revealed polysomy of chromosome 2 and no ALK amplification.Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women.Determination of HER2 and p53 Mutations by Sequence Analysis Method and EGFR/Chromosome 7 Gene Status by Fluorescence in Situ Hybridization for the Predilection of Targeted Therapy Modalities in Immunohistochemically Triple Negative Breast Carcinoma Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype.High EGFR gene copy number predicts poor outcome in triple-negative breast cancer.

P2860

Q28069867-F4DD99B0-CB1B-45CB-9305-A730545FF079 Q33646271-5CD7F1A5-ADE5-4175-8ACB-75FAA3E0B609 Q35012485-F5D7F519-6AA7-4A7C-BFC2-E985B15DF8BF Q35036895-58BAAC92-6479-4EE1-9C1F-1EADC9D6D887 Q35136824-C4BC8395-ED60-4763-B4A1-39B1FAE7C18D Q35214370-D62546F0-3C2F-4D72-AED9-3E040BFCFDD5 Q35833567-7E49A844-C722-4A6F-9315-C4C0BFC168EF Q36105958-0C07FF4A-C24E-4A3E-B180-FF55C77516D5 Q37164587-EE2FC7C2-1D2F-4FD3-BA24-DB3BB2B31BAE Q37232769-72C04CFA-692F-4A57-B36D-FF2CA21FD183 Q37323062-638066FD-46DE-49A9-B728-62E8228F2F59 Q37704344-9F1894ED-5A1F-4587-99DB-4033B8DA67CA Q38068566-F1877B21-7848-484E-A56C-FACD6A78F97E Q38084287-E1393727-F178-44B7-8088-4335ED369162 Q38084846-CE6948B3-828C-4934-B296-812CFBA6A087 Q38086421-6B3CC6A3-7694-4186-B947-66330DA05643 Q38259259-24645457-8A92-456E-A610-3783E6E90B29 Q38398043-968392D7-5AE3-4684-8E9C-51EFA5612686 Q40953806-6EC69AA4-652C-4988-869A-A97715702E62 Q41982188-2DC4ED90-C49A-4ECF-BF98-FBC61009EC29 Q42450636-5F237739-025A-4A89-A048-0906FCBC0F11 Q42478126-E84374B6-257F-404E-8CD4-B91E2DBABF01 Q42700663-7B15EC1F-926B-4FE4-992A-539B686905F4 Q53300836-8452E72C-2F3B-493D-9103-8B98A0EB22F5

P2860

Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.

http://www.wikidata.org/entity/Q42506718

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Rare oncogenic mutations of pr ...... triple-negative breast cancer.

@en

Rare oncogenic mutations of pr ...... triple-negative breast cancer.

@nl

type

label

Rare oncogenic mutations of pr ...... triple-negative breast cancer.

@en

Rare oncogenic mutations of pr ...... triple-negative breast cancer.

@nl

prefLabel

Rare oncogenic mutations of pr ...... triple-negative breast cancer.

@en

Rare oncogenic mutations of pr ...... triple-negative breast cancer.

@nl

P1433

Q42506718-BC7FD987-D46A-46C0-923E-76E18629C3B2

P1476

Q42506718-08F09EDA-F56D-43D7-8A2A-C9367A3F0E22

P2093

Q42506718-3E4BCC22-7F31-4186-964B-45E6A16451C4

Q42506718-43C13E7D-08BF-4B72-8910-6AD1041DF70F

Q42506718-50B1DEE8-17E2-4FB2-993D-89B2DEF4A24D

Q42506718-5F3A2467-7636-445D-BBD3-3A01AD100C18

Q42506718-60F23220-962F-46A7-BB0F-EADF34D2F845

Q42506718-83072717-7C84-411B-BDDA-07B0ECFF9D00

Q42506718-880DBC61-6AEF-4AB3-A637-9013475071CC

Q42506718-93868FB6-9429-4FD4-BC43-BF4627B6A63C

Q42506718-99589092-58E7-4A8E-989D-9A3749751CD4

Q42506718-E91E1C01-1B34-40B2-BCB0-431BFC209F36

P2860

Q42506718-004E8DE4-2D30-47C2-B9CB-867A60A68184

Q42506718-127E0912-CBCC-4196-A99F-593F8AD70070

Q42506718-21437118-1E09-424B-BA54-54AE2BB188DC

Q42506718-2677A823-F647-4B1D-8359-405AE1364459

Q42506718-2AC063FE-6E97-49BA-A819-9437A8A1F687

Q42506718-35B659F5-D26D-4844-90AA-405767E8D4DA

Q42506718-38866715-ADE1-481F-9437-308F56B97D87

Q42506718-44B1E7DE-C3C0-4CAD-B31A-CD042726A8A3

Q42506718-4DC7B44A-0B8C-4442-86AB-FFCA273C9BC0

Q42506718-4F6469F1-66F0-48AE-BF6D-2FC396C9DC83

P2888

Q42506718-B2CEC7DA-0F31-4EEE-A974-B1C67BA525F7

P304

Q42506718-44540C37-9E2C-4D2D-B3CD-5B659EC591B9

P31

Q42506718-61535E6E-0C16-49D9-BF9C-5FEA4F2DCEFA

P356

Q42506718-32C01B33-04BE-41AF-A468-4B2CBCC70880

P407

Q42506718-235AC869-9FA8-402F-9EB8-CD575E1F10DE

P433

Q42506718-F73029E4-759D-4457-B51E-1429BBAED8DD

P478

Q42506718-FD8FB71E-F053-4F8D-84DE-BAB8759275F5

P577

Q42506718-3A602561-7841-4F5F-8FC7-B467E1D1AC55

P6179

Q42506718-A464A7ED-FA5D-48A9-83CF-A90CB212E7BB

P698

Q42506718-3B87FF40-E692-4644-B5C8-96A511EA0126

P356

S10549-012-2092-7

P1433

Breast Cancer Research and Treatment

P1476

Rare oncogenic mutations of pr ...... triple-negative breast cancer.

@en

P2093

Alexander Quaas

http://www.w3.org/2001/XMLSchema#string

Annette Lebeau

http://www.w3.org/2001/XMLSchema#string

Christian Wilke

http://www.w3.org/2001/XMLSchema#string

Fritz Jaenicke

http://www.w3.org/2001/XMLSchema#string

Guido Sauter

http://www.w3.org/2001/XMLSchema#string

Matthias Choschzick

http://www.w3.org/2001/XMLSchema#string

Peter Paluchowski

http://www.w3.org/2001/XMLSchema#string

Stefan Geist

http://www.w3.org/2001/XMLSchema#string

Tobias J Grob

http://www.w3.org/2001/XMLSchema#string

Uwe Heilenkötter

http://www.w3.org/2001/XMLSchema#string

P2860

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.

Mutations of the BRAF gene in human cancer

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

Triple-Negative Breast Cancer

Ras oncogenes: split personalities

Tissue microarrays for high-throughput molecular profiling of tumor specimens

Diverse somatic mutation patterns and pathway alterations in human cancers

P2888

s10549-012-2092-7

P304

561-567

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-012-2092-7

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

134

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1011880175

http://www.w3.org/2001/XMLSchema#string

P698

22610646

http://www.w3.org/2001/XMLSchema#string